CLYM

Climb Bio

No price yet

Announcements

Nothing here yet

Daily updates

CLYM116 showed near-complete APRIL suppression and sustained IgA reduction in Phase 1Sep 3, 2026

FDA designations

Nothing here yet

News

Climb Bio reported Phase 1 data for CLYM116 showing a prolonged half-life and strong APRIL suppression, supporting dosing every 12 weeks in IgA nephropathySep 7, 2026
Climb Bio received FDA Fast Track designation for Budoprutug in kidney diseaseApr 7, 2026
Climb Bio announces CLYM116 preclinical data highlighting potential for best-in-class therapeutic for IgANSep 29, 2025